Eurofarma Laboratorios S.A.   Report issue

For profit Phase 2 Phase 3
Founded: Sao Paulo Brazil (1972)
Status: No NME R&D (1972)

Organization Overview

First Clinical Trial
2007
NCT05148377
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Eurofarma Laboratorios S.A. | Eurofarma Laboratórios S/A

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Adenocarcinoma (Phase 3)

Angina, Unstable (Phase 3)

Asthma (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Adenosquamous (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Cystitis (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Esophageal Neoplasms (Phase 3)

Esophagitis, Peptic (Phase 3)

Fractures, Bone (Phase 3)

Gastroesophageal Reflux (Phase 3)

Glioma (Phase 2)

Heart Failure (Phase 3)

Hip Fractures (Phase 3)

Hypertension (Phase 3)

Infarction (Phase 3)

Lactose Intolerance (Phase 3)

Low Back Pain (Phase 3)

Lung Neoplasms (Phase 3)

Migraine Disorders (Phase 3)

Myocardial Infarction (Phase 3)

Neutropenia (Phase 3)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Prostatic Neoplasms (Phase 3)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Perennial (Phase 3)

Sleep Initiation and Maintenance Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 43
  • # of Trial APIs: 46